The National Institute of Child Health and Human Development (NICHD) awarded The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a $167,000 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to study the impact of epigenetic regulation on lung stem cells in congenital lung diseases. The project aims to determine how genetic variants and pharmaceutical interventions affect the differentiation and self-renewal of patient-derived lung basal stem cells, as well as map the associated epigenetic changes. This foundational research leverages recent genetic breakthroughs in understanding congenital diaphragmatic hernia to develop potential therapies for a broader class of congenital lung diseases. The award has an initial project period from September 1, 2023 to August 31, 2025.
Generated 7/16/24, 10:46 AM